Details of the Drug Combination

General Information of Drug Combination (ID: DC48T1G)

Drug Combination Name
Esomeprazole Moxifloxacin
Indication
Disease Entry Status REF
Helicobacter Infections Phase 4 [1]
Component Drugs Esomeprazole   DM7BN0X Moxifloxacin   DMU8V4S
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Esomeprazole
Disease Entry ICD 11 Status REF
Cystic fibrosis CA25 Approved [2]
Gastrinoma 2C10.1 Approved [2]
Laryngeal disorder N.A. Approved [2]
Nausea MD90 Approved [2]
Peptic esophagitis N.A. Approved [2]
Peptic ulcer DA61 Approved [3]
Esomeprazole Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Gastric H(+)/K(+) ATPase (Proton pump) TTLOKXP ATP4A_HUMAN; ATP4B_HUMAN Modulator [6]
------------------------------------------------------------------------------------
Esomeprazole Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Esomeprazole Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Increases Expression [8]
------------------------------------------------------------------------------------
Indication(s) of Moxifloxacin
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [4]
Mycoplasma pneumoniae pneumonia N.A. Approved [5]
Peritonitis N.A. Approved [5]
Pneumonic plague N.A. Approved [5]
Septicemic plague N.A. Approved [5]
Staphylococcal pneumonia N.A. Approved [5]
Staphylococcus aureus infection N.A. Approved [5]
Streptococcal pneumonia N.A. Approved [5]
Tuberculosis 1B10-1B14 Approved [5]
Pneumonia caused by chlamydia N.A. Investigative [5]
Pneumonia due to Klebsiella pneumoniae CA40.03 Investigative [5]
Moxifloxacin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [6]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [6]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01792700) Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy
2 Esomeprazole FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5488).
4 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
5 Moxifloxacin FDA Label
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Predictive performance of physiologically based pharmacokinetic (PBPK) modeling of drugs extensively metabolized by major cytochrome P450s in children. Clin Pharmacol Ther. 2018 Jul;104(1):188-200.
8 The effects of drugs with immunosuppressive or immunomodulatory activities on xenobiotics-metabolizing enzymes expression in primary human hepatocytes. Toxicol In Vitro. 2015 Aug;29(5):1088-99.